Anti-MDA5 Antibody Spectrum in Western World

doi:10.1007/s11926-018-0798-1

Review

. 2018 Oct 31;20(12):78.

doi: 10.1007/s11926-018-0798-1.

Anti-MDA5 Antibody Spectrum in Western World

Siamak Moghadam-Kia^{1

2}, Chester V Oddis¹, Rohit Aggarwal³

Affiliations

¹ Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
² VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
³ Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. aggarwalr@upmc.edu.

PMID: 30382445
DOI: 10.1007/s11926-018-0798-1

Review

Anti-MDA5 Antibody Spectrum in Western World

Siamak Moghadam-Kia et al. Curr Rheumatol Rep. 2018.

. 2018 Oct 31;20(12):78.

doi: 10.1007/s11926-018-0798-1.

Authors

Siamak Moghadam-Kia^{1

2}, Chester V Oddis¹, Rohit Aggarwal³

Affiliations

¹ Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
² VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
³ Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. aggarwalr@upmc.edu.

PMID: 30382445
DOI: 10.1007/s11926-018-0798-1

Abstract

Purpose of review: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) is a novel and highly specific myositis-associated autoantibody, which defines a unique phenotype among patients with dermatomyositis (DM).

Recent findings: Anti-MDA5 was originally characterized in Japan in DM patients with hallmark cutaneous features and no proximal muscle weakness and termed clinically amyopathic DM (CADM). Anti-MDA5 has characteristic cutaneous manifestations which include tender palmar papules and cutaneous ulcerations, along with an increased frequency of interstitial lung disease (ILD) that can be rapidly progressive (RPILD) and fatal. This review will highlight the clinical significance of anti-MDA5 autoantibodies in Caucasian DM patients.

Keywords: Anti-MDA5 autoantibody; Classic dermatomyositis (DM); Clinical features; Clinically amyopathic dermatomyositis (CADM).

PubMed Disclaimer

Cited by

Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Kishida D, Ushiyama S, Shimojima Y, Ueno KI, Kurashina JI, Shirai T, Sekijima Y. Kishida D, et al. Intern Med. 2021 Aug 15;60(16):2697-2700. doi: 10.2169/internalmedicine.6931-20. Epub 2021 Mar 8. Intern Med. 2021. PMID: 33678748 Free PMC article.
Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications.
Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X, Xue J, Lian X, Ma J, Hao P, Lu L, Ye S, Shen N, Bao C, Fu Q, Zhang X. Ye Y, et al. Nat Commun. 2022 Oct 29;13(1):6458. doi: 10.1038/s41467-022-34145-4. Nat Commun. 2022. PMID: 36309526 Free PMC article.
Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis.
Strauss T, Günther C, Schnabel A, Wolf C, Hahn G, Lee-Kirsch MA, Brück N. Strauss T, et al. Pediatr Rheumatol Online J. 2023 Sep 19;21(1):104. doi: 10.1186/s12969-023-00894-9. Pediatr Rheumatol Online J. 2023. PMID: 37726751 Free PMC article.
Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti-MDA5 dermatomyositis.
Jiang Y, Liu Y, Zhao Y, Zheng Y, Yu M, Deng J, Hao H, Zhang W, Wang Z, Yuan Y. Jiang Y, et al. Ann Clin Transl Neurol. 2021 Mar;8(3):677-686. doi: 10.1002/acn3.51311. Epub 2021 Feb 12. Ann Clin Transl Neurol. 2021. PMID: 33576578 Free PMC article.
Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY, Suh CH, Kim YG, Park YB, Shim SC, Lee SH, Lee SS, Bae SC, Yoo DH. Ahn GY, et al. J Korean Med Sci. 2020 Sep 28;35(38):e335. doi: 10.3346/jkms.2020.35.e335. J Korean Med Sci. 2020. PMID: 32989931 Free PMC article.

See all "Cited by" articles

References

1. Rheumatology (Oxford). 2010 Sep;49(9):1713-9 - PubMed
1. J Am Acad Dermatol. 2006 Apr;54(4):597-613 - PubMed
1. Clin Rheumatol. 2016 Aug;35(8):2125-2130 - PubMed
1. J Rheumatol. 2005 Sep;32(9):1719-26 - PubMed
1. N Engl J Med. 1975 Feb 13;292(7):344-7 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Rheumatology (Oxford). 2010 Sep;49(9):1713-9 - PubMed

[2] Rheumatology (Oxford). 2010 Sep;49(9):1713-9 - PubMed

[3] J Am Acad Dermatol. 2006 Apr;54(4):597-613 - PubMed

[4] J Am Acad Dermatol. 2006 Apr;54(4):597-613 - PubMed

[5] Clin Rheumatol. 2016 Aug;35(8):2125-2130 - PubMed

[6] Clin Rheumatol. 2016 Aug;35(8):2125-2130 - PubMed

[7] J Rheumatol. 2005 Sep;32(9):1719-26 - PubMed

[8] J Rheumatol. 2005 Sep;32(9):1719-26 - PubMed

[9] N Engl J Med. 1975 Feb 13;292(7):344-7 - PubMed

[10] N Engl J Med. 1975 Feb 13;292(7):344-7 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Anti-MDA5 Antibody Spectrum in Western World

Affiliations

Anti-MDA5 Antibody Spectrum in Western World

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials